



30 Hudson Street
Jersey City, NJ 07302

NOTICE TO 340B COVERED ENTITIES REGARDING ORGANON'S 340B PROGRAM INTEGRITY INITIATIVE AND APPLICABLE EXEMPTIONS IN ARKANSAS, COLORADO, HAWAII, KANSAS, LOUISIANA, MAINE, MARYLAND, MINNESOTA, MISSISSIPPI, MISSOURI, NEBRASKA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, OREGON, RHODE ISLAND, SOUTH DAKOTA, UTAH, VERMONT, AND WEST VIRGINIA

[SEE PAGE 2](#)

NEXT STEPS AND FREQUENTLY ASKED QUESTIONS

[SEE PAGE 4](#)

**EXHIBIT A
ORGANON PRODUCTS COVERED BY THIS POLICY**

[SEE PAGE 7](#)

**EXHIBIT B
PRIOR ORGANON 340B PROGRAM ANNOUNCEMENTS AND UPDATES**

[SEE PAGE 7](#)

Note: This message was distributed from an e-mail account used for sending messages only. Please do not reply to this message. 2026 Organon group of companies. All rights reserved ORGANON and the ORGANON logo are trademarks of the Organon group of companies.

Organon Privacy Office: 30 Hudson St. Jersey City, NJ 07302, USA

NOTICE TO 340B COVERED ENTITIES REGARDING ORGANON'S 340B PROGRAM

April 1, 2026

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications.

This letter provides you notice that Organon is updating its approach to 340B policy management and claims collection and will begin using the Truzo™ platform from Kalderos to facilitate contract pharmacy designations and claims data collection. As a result, **starting May 1, 2026, 340B covered entities must submit claims data, in line with the requirements and exceptions detailed in Organon’s policy, via the Truzo platform if they wish to continue receiving access to the 340B price for Organon’s products dispensed through contract pharmacies.** The Truzo platform is available to 340B covered entities at no cost.

Aside from the transition to Truzo, no other changes to Organon’s 340B policy are being made at this time. A summary of our current policy¹ and instructions on how to register with Truzo follow.

Subject to the exemptions noted below, Organon will:

- (a) provide products purchased at the 340B price to locations registered as 340B covered entities or as Ship To locations for 340B covered entities; and
- (b) decline to facilitate Bill To/ Ship To orders for (i) all hospital covered entities² and (ii) HRSA-Funded Health Center (CH) grantees.³

Any hospital covered entity or CH grantee, regardless of whether it has an in-house pharmacy capable of dispensing 340B purchased drugs, may designate a single contract pharmacy location if the covered entity provides claims data for the designated single contract pharmacy through Truzo.

The following exemptions apply to covered entities located in the following states:

Implementation Dates (i.e., for orders placed on or after applicable implementation date)	Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies within the exempt state.	Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies within the exempt state. <i>Additional requirement:</i> ⁴ Must provide claims level data via Truzo
December 1, 2023		Arkansas Louisiana
June 6, 2024	West Virginia	Kansas Maryland Mississippi

¹ See Exhibit B for Organon’s previous 340B program announcement and updates.

² Organon 340B program update dated June 1, 2023 (Exhibit B).


³ Organon 340B program update dated December 1, 2024 (Exhibit B). Federal grantees with entity types other than CH will continue to remain eligible for Bill To/ Ship To arrangements for Organon products at the 340B discounted price and do not need to submit 340B claims.

⁴ 340B claims for contract pharmacies must be submitted within 45 days of the date of dispense for the contract pharmacy to remain eligible to receive 340B purchased drugs. Please refer the FAQs section for details.

August 1, 2024		Minnesota
August 28, 2024		Missouri
April 9, 2025	Nebraska	
May 7, 2025	Utah	
June 11, 2025	Vermont	
July 1, 2025	South Dakota	Hawaii
August 1, 2025	North Dakota	
August 6, 2025	Colorado	
September 24, 2025	Maine	
September 29, 2025	Oregon	
October 1, 2025	Rhode Island	
November 1, 2025	Oklahoma	
January 1, 2026	New Mexico (CH Federal Grantees only)	

If you have any questions regarding this policy or how to claim your Truzo account, please contact truzo-support@kalderos.com.

Best Regards,

 Electronically signed by: Shannon Smallwood
Reason: Approved
Date: Mar 30, 2026 19:47:26 EDT

Shannon Smallwood, PharmD, BCPS
Director, Market Access Operations and Planning Organon Market Access & Account Management



30 Hudson Street
Jersey City, NJ 07302

NEXT STEPS AND FREQUENTLY ASKED QUESTIONS

Covered entities should register with Truzo, a web-based platform made available to covered entities at no cost.

To get started with the Truzo platform, follow these three steps:

- (a) **Set-up your account:** The Authorizing Official (AO) for your covered entity, should claim their profile by going to truzo.kalderos.com/request/signup. The AO can designate a Primary Administrator (PA) and additional roles as needed.
- (b) **Make attestations:** The PA for the account will be asked to attest whether they have any entity-owned pharmacies and review any child sites or contract pharmacies linked to your covered entity. The PA will also need to provide the NPI & HIN for your covered entity as well as any associated entity-owned pharmacies, contract pharmacies, and, if appropriate, child sites, by selecting “Covered Entity Management” from the navigation menu.
- (c) **Designate pharmacies:** The final step is to make your pharmacy designation(s) in line with Organon’s 340B policy. Select “Pharmacy Designation Center” from the navigation menu and choose the manufacturer that you wish to update. As specified in the individual 340B policy, add the entity-owned and/or contract pharmacies you intend to use for that manufacturer. Pharmacy designations are specific to each manufacturer.

If you need help at any stage, feel free to visit gotruzo.com/ce-onboarding for instruction guides & videos or email truzo-support@kalderos.com.

Frequently Asked Questions

Q: Which products are subject to Organon’s policy?

A: Organon’s contract pharmacy policy applies to all Organon products. Organon’s policy letter can be found at <https://gotruzo.com/manufacturer-policies/> and a list of applicable NDCs is attached to this notice as Exhibit A.

Q: My covered entity has a contract pharmacy relationship with a pharmacy that is owned by our health system. Is this pharmacy subject to Organon’s policy?

A: A covered entity may elect to designate any contract pharmacy location registered on the HRSA OPAIS database, regardless of ownership interest, as its single contract pharmacy location so long as it complies with the claims submission requirements noted below.

- A covered entity that does not have an in-house pharmacy capable of dispensing 340B purchased drugs to its patients may designate a single contract pharmacy location for delivery of 340B-priced drugs if the covered entity provides claims data for the designated single contract pharmacy.
- A covered entity that does have an in-house pharmacy capable of dispensing 340B purchased drugs to its patients may designate a single contract pharmacy location for delivery of 340B-priced drugs if the covered entity provides claims data for the designated single contract pharmacy.

Q: My covered entity has an in-house pharmacy that is capable of purchasing and dispensing Organon drugs, but my entity doesn’t use it to dispense Organon drugs. Can my entity designate one contract pharmacy?

A: Yes, under Organon’s policy, a covered entity that has an in-house pharmacy capable of dispensing 340B purchased drugs to its patients may designate a single contract pharmacy for delivery of 340B priced drugs if the covered entity provides claims data for the designated single contract pharmacy.

Q. My 340B covered entity has contract pharmacy arrangements with multiple locations of the same pharmacy (e.g. six different Accredo pharmacy locations). Can my entity designate all locations of the same pharmacy?

A. No. Organon's policy allows 340B covered entities to designate a single contract pharmacy location. Contract pharmacy locations are registered individually on the HRSA database and 340B covered entities are permitted to designate only a single contract pharmacy location which corresponds to a single contract pharmacy registration with HRSA.

Q. Are there any exceptions to your policy that would allow a 340B covered entity to designate more than one contract pharmacy?

A. Exceptions to this policy include: (i) Federal grantees with entity type other than HRSA-Funded Health Center (CH), which may continue to obtain products at the 340B price through multiple contract pharmacy locations, and (ii) covered entities located in states that have enacted legislation limiting restrictions.

Q. My 340B covered entity has already designated a contract pharmacy on your previous platform. Do I need to redesignate?

A. Yes. With the move to Truzo, the Authorizing Official for your covered entity will first need to claim their Truzo account. This is a one-time step and provides you with access to the Truzo platform for Organon as well as any other manufacturers who use Truzo to administer their 340B policy. Once the account is claimed, you will be able to designate your contract pharmacy in line with our policy.

Q. My 340B covered entity has already registered on Truzo. How do I designate my contract pharmacy?

A. Once you are logged into your Truzo account, select "Pharmacy Designations" from the navigation menu and choose Organon from the list of manufacturers.

Q. How often can my covered entity change its contract pharmacy designation?

A. Covered entities may change their contract pharmacy designation once every twelve (12) months (from the date of first designation) or more often as agreed to by Organon and the covered entity (e.g., if the designated contract pharmacy relationship is terminated from the HRSA OPAIS database).

Q. How does my covered entity change its contract pharmacy designation?

A. Changes to contract pharmacy designations can be made by logging into the covered entity's account at <https://truzo.kalderos.com/request> and selecting "Pharmacy Designations" in the navigation bar. 340B covered entities can visit gotruzo.com/ce-onboarding for instruction guides & videos or email truzo-support@kalderos.com for support.

Q. Is Organon requiring covered entities to have a HIN registered for the contract pharmacy that they designate?

A. Yes, a contract pharmacy must have a HIN assigned to it for a covered entity to designate it as its single contract pharmacy. This information is important for Organon to manage its process with its wholesalers. If a covered entity needs guidance or more information on how to get a HIN assigned to a contract pharmacy, please reach out to your wholesale distributor.

Q. If the contract pharmacy my covered entity wants to designate doesn't have a HIN, how does my entity get one?

A: Organon will not register a HIN on your behalf, however if you need guidance or more information on how to get a HIN assigned to your contract pharmacy, please reach out to your wholesale distributor.

Q: My covered entity would like to submit 340B claims for its designated contract pharmacy to continue purchasing Organon products at the 340B price through this location. What does our entity need to do to begin submitting 340B claims?

A: 340B covered entities that wish to submit 340B claims for its designated contract pharmacy under Organon's policy can do so by registering a Truzo account at <https://truzo.kalderos.com/request/signup>. Users that have registered an account with Truzo™ can begin submitting 340B claims for Organon by signing in to their Truzo account and then navigating to the Data Submission option in the menu located on the left side of your browser window. 340B claims must be submitted within 45 days of the date of dispense in order for the contract pharmacy to remain eligible to receive 340B purchased drugs.

Q: Does Organon restrict Federal Grantees?

A: Beginning December 1st, 2024, Organon's policy will apply to HRSA-Funded Health Center (CH) entity types. For clarity, and in conformity with the 340B Office of Pharmaceutical Affairs definition, CH covered entities include Community Health Centers (CHC) and those entity types formerly identified as a School Based Program (340S), Health Care for the Homeless Program (HO), Migrant Health Program (MH), and Public Housing Primary Care Program (PH). Organon does not restrict access to 340B pricing for 340B contract pharmacy locations for any other Federal grantee.

Q: Are entities located in certain states exempted from this policy?

A: Covered entities in certain states are exempt from the limited contract pharmacy approach, and continue to remain eligible for unlimited Bill To/ Ship To arrangements, according to state legislative requirements, as previously notified and summarized in Organon's most recent policy letter update.

Q: Can I contract with a pharmacy in another state?

A: Organon adheres to state-specific legislation permitting the dispensing of 340B drugs through an unlimited number of pharmacies contracted by the covered entities. The state laws/legislations apply only to covered entities within the state, not outside, and in the same vein, Organon is applying the exemptions to pharmacies contracted by the covered entities within the state.

Q: Is there a limitation on how far back replenishment orders can be placed and still receive 340B pricing once eligibility for our contract pharmacy designation has been processed by our wholesaler?

A: Contract pharmacy replenishment orders for covered entities registered with Truzo™ will be honored for prescriptions dispensed to eligible 340B patients within forty-five (45) days of each data submission to Truzo™.



30 Hudson Street
Jersey City, NJ 07302

EXHIBIT A – ORGANON NDCs

78206-0111-01	78206-0112-01	78206-0113-01	78206-0114-01
78206-0114-02	78206-0114-03	78206-0114-04	78206-0115-01
78206-0118-01	78206-0120-01	78206-0121-01	78206-0122-01
78206-0122-02	78206-0123-01	78206-0123-02	78206-0124-01
78206-0124-02	78206-0125-01	78206-0126-01	78206-0126-02
78206-0127-01	78206-0127-02	78206-0129-01	78206-0130-01
78206-0131-01	78206-0135-01	78206-0136-01	78206-0137-01
78206-0138-01	78206-0138-02	78206-0139-01	78206-0139-02
78206-0140-01	78206-0140-02	78206-0141-01	78206-0141-02
78206-0142-01	78206-0142-99	78206-0143-01	78206-0143-99
78206-0145-01	78206-0146-01	78206-0146-03	78206-0147-01
78206-0147-99	78206-0148-01	78206-0148-99	78206-0150-01
78206-0150-99	78206-0152-01	78206-0152-02	78206-0153-01
78206-0153-02	78206-0156-01	78206-0156-99	78206-0158-01
78206-0158-99	78206-0159-01	78206-0159-99	78206-0160-01
78206-0161-01	78206-0162-01	78206-0162-99	78206-0166-01
78206-0168-01	78206-0170-01	78206-0171-01	78206-0172-01
78206-0172-02	78206-0173-01	78206-0174-01	78206-0174-02
78206-0175-01	78206-0175-02	78206-0176-01	78206-0176-02
78206-0177-01	78206-0177-02	78206-0178-01	78206-0180-01
78206-0180-02	78206-0181-01	78206-0181-02	78206-0182-01
78206-0182-02	78206-0183-01	78206-0183-99	78206-0184-01
78206-0184-99	78206-0186-01	78206-0186-99	78206-0187-01
78206-0187-99	78206-0188-01	78206-0189-01	78206-0190-01
81672-5051-01			



30 Hudson Street
Jersey City, NJ 07302

EXHIBIT B

NOTICE OF DECEMBER 31, 2025: Program Update Applicable to New Mexico

December 31, 2025

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications.

This letter provides a summary of Organon’s current approach to the offering of 340B prices to covered entities transferring 340B drugs to contract pharmacies.¹

Subject to the exemptions noted below, Organon will:

- (a) provide products purchased at the 340B price to locations registered as 340B covered entities or as Ship To locations for 340B covered entities; and
- (b) decline to facilitate Bill To/ Ship To orders for (i) all hospital covered entities² and (ii) HRSA-Funded Health Center (CH) grantees.³

Any hospital covered entity or CH grantee, regardless of whether it has an in-house pharmacy capable of dispensing 340B purchased drugs, may designate a single contract pharmacy location if the covered entity provides claims data for the designated single contract pharmacy through 340B ESP™.

The following exemptions apply to covered entities located in the following states:

Implementation Dates (i.e., for orders placed on or after applicable implementation date)	Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies within the exempt state.	Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies within the exempt state. <i>Additional requirement:</i> ⁴ Must provide claims level data via 340B ESP™
December 1, 2023		Arkansas Louisiana
June 6, 2024	West Virginia	Kansas Maryland Mississippi

¹ See Exhibit A for Organon’s previous 340B program announcement and updates.

² Organon 340B program update dated June 1, 2023 (Exhibit A).

³ Organon 340B program update dated December 1, 2024 (Exhibit A). Federal grantees with entity types other than CH will continue to remain eligible for Bill To/ Ship To arrangements for Organon products at the 340B discounted price and do not need to submit 340B claims.

⁴ 340B claims for contract pharmacies must be submitted within 45 days of the date of dispense for the contract pharmacy to remain eligible to receive 340B purchased drugs. Please refer the FAQs section for details.



30 Hudson Street
Jersey City, NJ 07302

August 1, 2024		Minnesota
August 28, 2024		Missouri
April 9, 2025	Nebraska	
May 7, 2025	Utah	
June 11, 2025	Vermont	
July 1, 2025	South Dakota	Hawaii
August 1, 2025	North Dakota	
August 6, 2025	Colorado	
September 24, 2025	Maine	
September 29, 2025	Oregon	
October 1, 2025	Rhode Island	
November 1, 2025	Oklahoma	
January 1, 2026	New Mexico (CH Federal Grantees only)	

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the Next Steps and FAQs on how to register an account.

If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Best Regards,

Shannon Smallwood, PharmD, BCPS
Director, Market Access Operations and Planning Organon Market Access & Account Management



30 Hudson Street
 Jersey City, NJ 07302

NOTICE OF OCTOBER 7, 2025: Program Update Applicable to all states

October 7, 2025

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications.

This letter provides a summary of Organon’s current approach to the offering of 340B prices to covered entities transferring 340B drugs to contract pharmacies.⁵

Subject to the exemptions noted below, Organon will:

- (a) provide products purchased at the 340B price to locations registered as 340B covered entities or as Ship To locations for 340B covered entities; and
- (b) decline to facilitate Bill To/ Ship To orders for (i) all hospital covered entities⁶ and (ii) HRSA-Funded Health Center (CH) grantees.⁷

Any hospital covered entity or CH grantee, regardless of whether it has an in-house pharmacy capable of dispensing 340B purchased drugs, may designate a single contract pharmacy location if the covered entity provides claims data for the designated single contract pharmacy through 340B ESP™.

The following exemptions apply to covered entities located in the following states:

Implementation Dates (i.e., for orders placed on or after applicable implementation date)	Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies within the exempt state.	Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies within the exempt state. <i>Additional requirement:</i> ⁸ Must provide claims level data via 340B ESP™
December 1, 2023		Arkansas

⁵ See Exhibit A for Organon’s previous 340B program announcement and updates.

⁶ Organon 340B program update dated June 1, 2023 (Exhibit A).

⁷ Organon 340B program update dated December 1, 2024 (Exhibit A). Federal grantees with entity types other than CH will continue to remain eligible for Bill To/ Ship To arrangements for Organon products at the 340B discounted price and do not need to submit 340B claims.

⁸ 340B claims for contract pharmacies must be submitted within 45 days of the date of dispense for the contract pharmacy to remain eligible to receive 340B purchased drugs. Please refer the FAQs section for details.



30 Hudson Street
 Jersey City, NJ 07302

		Louisiana
June 6, 2024	West Virginia	Kansas Maryland Mississippi
August 1, 2024		Minnesota
August 28, 2024		Missouri
April 9, 2025	Nebraska	
May 7, 2025	Utah	
June 11, 2025	Vermont	
July 1, 2025	South Dakota	Hawaii
August 1, 2025	North Dakota	
August 6, 2025	Colorado	
September 24, 2025	Maine	
September 29, 2025	Oregon	
October 1, 2025	Rhode Island	
November 1, 2025	Oklahoma	

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the Next Steps and FAQs on how to register an account.

If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Best Regards,

Andrew Tedeschi
 Head of US Market Access and Account Management



30 Hudson Street
 Jersey City, NJ 07302

NOTICE OF JULY 14, 2025: Program Update Applicable to Colorado, Hawaii, North Dakota, South Dakota, and Vermont

July 14, 2025

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications.

This letter provides a summary of Organon’s current approach to the offering of 340B prices to covered entities transferring 340B drugs to contract pharmacies.

Subject to the exemptions noted below, Organon will:

- (a) provide products purchased at the 340B price to locations registered as 340B covered entities or as Ship To locations for 340B covered entities; and
- (b) decline to facilitate Bill To/ Ship To orders for (i) all hospital covered entities⁹ and (ii) HRSA-Funded Health Center (CH) grantees.¹⁰

Any hospital covered entity or CH grantee, regardless of whether it has an in-house pharmacy capable of dispensing 340B purchased drugs, may designate a single contract pharmacy location if the covered entity provides claims data for the designated single contract pharmacy through 340B ESP™.

The following exemptions apply to covered entities located in the following states:

Implementation Dates (i.e., for orders placed on or after applicable implementation date)	Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies	Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies. <i>Additional requirement:</i> ¹¹ Must provide claims level data via 340B ESP™
December 1, 2023		Arkansas Louisiana
June 6, 2024	West Virginia	Kansas

⁹ Organon 340B program update dated June 1, 2023 (Exhibit A).

¹⁰ Organon 340B program update dated December 1, 2024 (Exhibit A). Federal grantees with entity types other than CH will continue to remain eligible for Bill To/ Ship To arrangements for Organon products at the 340B discounted price and do not need to submit 340B claims.

¹¹ 340B claims for contract pharmacies must be submitted within 45 days of the date of dispense for the contract pharmacy to remain eligible to receive 340B purchased drugs. Please refer the FAQs section for details.



30 Hudson Street
Jersey City, NJ 07302

		Maryland Mississippi
August 1, 2024		Minnesota
August 28, 2024		Missouri
April 9, 2025	Nebraska	
May 7, 2025	Utah	
June 11, 2025	Vermont	
July 1, 2025	South Dakota	Hawaii
August 1, 2025	North Dakota	
August 6, 2025	Colorado	

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the Next Steps and FAQs on how to register an account.

If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Best Regards,

Andrew Tedeschi
Head of US Market Access and Account Management



30 Hudson Street
Jersey City, NJ 07302

NOTICE OF MAY 9, 2025: Program Update and Summary

May 9, 2025

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications.

This letter is intended to provide a consolidated summary of Organon's approach to the offering of 340B prices to covered entities transferring 340B drugs to contract pharmacies (as previously communicated on June 1, 2023, November 1, 2023, June 6, 2024, August 1, 2024, and October 15, 2024), as well as an update to the list of states that are exempted from this approach:

- Except as provided below and subject to the exemption applicable to the Exempt States, Organon only provides products purchased at the 340B price to locations registered as 340B covered entities or as Ship To locations for 340B covered entities and will decline to facilitate Bill To/ Ship To orders for (i) all hospital covered entities¹² and (ii) HRSA-Funded Health Center (CH) grantees.¹³
- Federal grantees with entity types other than CH will continue to remain eligible for Bill To/ Ship To arrangements for Organon products at the 340B discounted price and do not need to submit 340B claims.
- Any hospital covered entity or CH grantee, regardless of whether it has an in-house pharmacy capable of dispensing 340B purchased drugs to its patients, may designate a single contract pharmacy location if the covered entity provides claims data for the designated single contract pharmacy through 340B ESP™.

Organon has implemented the following changes related to its 340B contract pharmacy policy applicable to the Exempt States, which include **Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, Missouri, Nebraska, Utah, and West Virginia**. Hospital covered entities and CH grantees located in the Exempt States are exempted from Organon's 340B policy as provided below and with the corresponding implementation dates:

- For covered entities located in **Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, and Missouri**:
 - Ability to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies provided claims level data is submitted via 340B ESP for these pharmacies.
 - 340B claims must be submitted within 45 days of the date of dispense in order for the contract pharmacy to remain eligible to receive 340B purchased drugs.
 - If a covered entity does not adhere to the 340B claims submissions requirement, the covered entity will be considered out of compliance, and the 340B discount for Organon products will no longer be permitted.

¹² Organon 340B program update dated June 1, 2023 (Exhibit A).

¹³ Organon 340B program update dated December 1, 2024 (Exhibit A).



30 Hudson Street
Jersey City, NJ 07302

- Covered entities located in **Nebraska, Utah, and West Virginia** will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies with no claims submission requirements. Accordingly, there is no action required by covered entities in these states with respect to this policy.

Changes to Organon's 340B contract pharmacy policy with respect to the Exempt States are subject to the following implementation dates (i.e., for orders placed on or after the applicable implementation date):

- May 7, 2025 for Utah
- April 9, 2025 for Nebraska
- August 28, 2024 for Missouri
- August 1, 2024 for Minnesota
- June 6, 2024 for Kansas, Maryland, Mississippi, West Virginia
- December 1, 2023 for Arkansas and Louisiana

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the Next Steps and FAQs on how to register an account.

If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Best Regards,

Andrew Tedeschi
Head of US Market Access and Account Management



30 Hudson Street
Jersey City, NJ 07302

NOTICE OF OCTOBER 15, 2024: Program Update Applicable to HRSA-Funded Health Center Grantees

October 15, 2024

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications. This letter is intended to provide you notice that Organon is updating its approach to the offering of 340B prices to certain Federal grantees transferring 340B drugs to contract pharmacies. This update is in addition to, and supplements, Organon's policy approach applicable to hospital covered entities (as previously detailed in the letter notice dated June 1, 2023).

Effective December 1, 2024, Organon will only provide products purchased at the 340B price to locations registered as 340B covered entities and will decline to facilitate Bill To/ Ship To orders for HRSA-Funded Health Center (CH) grantees, subject to the exceptions outlined below. For clarity, and in conformity with the 340B Office of Pharmaceutical Affairs definition, the CH covered entity type is inclusive of Community Health Centers (CHC) and those entity types formerly identified as a School Based Program (340S), Health Care for the Homeless Program (HO), Migrant Health Program (MH), and Public Housing Primary Care Program (PH).

Organon's updated policy will apply to CH covered entities/grantees. Federal grantees with entity types other than CH will continue to remain eligible for Bill To/ Ship To arrangements for Organon products at the 340B discounted price and do not need to submit 340B claims.

Any CH Federal grantee, regardless of whether it has an in-house pharmacy capable of dispensing 340B purchased drugs to its patients, may designate a single contract pharmacy location if the covered entity provides claims data for the designated single contract pharmacy through 340B ESP™.

Covered entities will have the following exemptions to the limited contract pharmacy approach, and continue to remain eligible for unlimited Bill To/ Ship To arrangements, according to state legislative requirements, as previously notified and summarized here:

- Covered entities located in Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, and Missouri, will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies provided that claims level data is submitted via 340B ESP for these pharmacies.
- Covered entities located in Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, and Missouri that do not adhere to the 340B claims submissions requirement will be considered to be out of compliance, and the 340B discount for Organon products will no longer be permitted. 340B claims must be submitted within 45 days of the date of dispense in order for the contract pharmacy to remain eligible to receive 340B purchased drugs.
- Covered entities located in West Virginia will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies with no claims submission requirements. Accordingly, there is no action required by covered entities in the state of West Virginia with respect to this policy.

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the



30 Hudson Street
Jersey City, NJ 07302

Next Steps and FAQs on how to register an account. If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Covered entities must take action by November 15th, 2024, in order for contract pharmacy location designations to take effect on the effective date of this policy.

Organon is committed to ensuring that all 340B covered entities can purchase Organon products at the 340B discounted price. 340B covered entities newly included in this policy should work with their contract pharmacy administrators and wholesalers to process any outstanding Bill To/ Ship To orders in advance of the December 1, 2024 effective date. Please refer to the Next Steps and FAQs for more information.

Best Regards,

A handwritten signature in black ink that reads "Andrew Tedeschi".

Andrew Tedeschi
Head of US Market Access and Account Management



30 Hudson Street
Jersey City, NJ 07302

NOTICE OF AUGUST 1, 2024: Program Update Applicable to Minnesota

August 1, 2024

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications. This letter is intended to provide you notice that Organon is altering its approach to the offering of 340B prices to covered entities located in Minnesota transferring 340B drugs to contract pharmacies.

Following our notification to you dated June 1, 2023, Organon will be implementing the changes described below related to its 340B contract pharmacy policy.

Effective August 1, 2024 and until further notice, Organon is adopting the following:

- Covered entities located in Minnesota will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies provided claims level data is submitted via 340B ESP for these pharmacies.
- If a Minnesota covered entity does not adhere to the 340B claims submissions requirement, the covered entity will be considered out of compliance and the 340B discount for Organon products will no longer be permitted. 340B claims must be submitted within 45 days of the date of dispense in order for the contract pharmacy to remain eligible to receive 340B purchased drugs.

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the Next Steps and FAQs below on how to register an account.

If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Best Regards,

Andrew Tedeschi
Head of US Market Access and Account Management



30 Hudson Street
Jersey City, NJ 07302

NOTICE OF AUGUST 1, 2024: Program Update Applicable to Missouri

August 1, 2024

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications. This letter is intended to provide you notice that Organon is altering its approach to the offering of 340B prices to covered entities located in Missouri transferring 340B drugs to contract pharmacies.

Following our notification to you dated June 1, 2023, Organon will be implementing changes described below related to its 340B contract pharmacy policy.

Effective August 28, 2024 and until further notice, Organon is adopting the following:

- Covered entities located in Missouri will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies provided claims level data is submitted via 340B ESP for these pharmacies.
- If a Missouri covered entity does not adhere to the 340B claims submissions requirement, the covered entity will be considered out of compliance and the 340B discount for Organon products will no longer be permitted. 340B claims must be submitted within 45 days of the date of dispense in order for the contract pharmacy to remain eligible to receive 340B purchased drugs.

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the Next Steps and FAQs on how to register an account.

If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Best Regards,

Andrew Tedeschi
Head of US Market Access and Account Management



30 Hudson Street
Jersey City, NJ 07302

NOTICE OF JUNE 6, 2024: Program Update Applicable to Kansas, Maryland, and Mississippi

June 6, 2024

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications. This letter is intended to provide you notice that Organon is altering its approach to the offering of 340B prices to covered entities located in Mississippi and West Virginia transferring 340B drugs to contract pharmacies.

Following our notification to you earlier this year, Organon will be implementing changes described below related to its 340B contract pharmacy policy.

Effective June 6th, 2024 and until further notice, Organon is adopting the following:

- Covered entities located in Kansas, Maryland, and Mississippi will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies provided claims level data is submitted via 340B ESP for these pharmacies.
- If a Kansas, Maryland, or Mississippi covered entity does not adhere to the 340B claims submissions requirement, the covered entity will be considered out of compliance and the 340B discount for Organon products will no longer be permitted. 340B claims must be submitted within 45 days of the date of dispense in order for the contract pharmacy to remain eligible to receive 340B purchased drugs.
- Covered entities located in West Virginia will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies with no claims submission requirements. Accordingly, there is no action required by covered entities in the state of West Virginia with respect to this policy.

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the Next Steps and FAQs on how to register an account.

If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Best Regards,

Andrew Tedeschi
Head of US Market Access and Account Management



30 Hudson Street
Jersey City, NJ 07302

NOTICE OF NOVEMBER 1, 2023: Program Update Applicable to Arkansas and Louisiana

November 1, 2023

Dear 340B Covered Entities,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications. This letter is intended to provide you notice that Organon is altering its approach to the offering of 340B prices to covered entities located in Louisiana and Arkansas transferring 340B drugs to contract pharmacies.

Following our notification to you earlier this year, Organon will be implementing changes described below related to its 340B contract pharmacy policy.

Effective December 1st, 2023 and until further notice, Organon is adopting the following:

- Covered entities located in Arkansas and Louisiana will be able to place Bill To / Ship To replenishment orders through an unlimited number of contract pharmacies provided claims level data is submitted via 340B ESP for these pharmacies.
- If an Arkansas or Louisiana covered entity does not adhere to the 340B claims submissions requirement, the covered entity will be considered out of compliance and the 340B discount for Organon products will no longer be permitted. 340B claims must be submitted within 45 days of the date of dispense in order for the contract pharmacy to remain eligible to receive 340B purchased drugs.

Organon will continue to utilize the 340B ESP™ platform to support this policy and receive claim submissions. While covered entities are not required to take any action regarding contract pharmacy designations, a registered account with Second Sight Solutions' 340B ESP™ platform is needed for claim submissions. Please refer to the Next Steps and FAQs on how to register an account.

If you have any questions about this initiative, please contact 340B ESP™ at support@340BESP.com.

Best Regards,

Andrew Tedeschi
Head of US Market Access and Account Management



30 Hudson Street
Jersey City, NJ 07302

NOTICE OF JUNE 1, 2023: Organon's 340B Program Update for Hospital Covered Entities (UPDATE HAS SINCE BEEN AMENDED)

June 1, 2023

Dear 340B Covered Entity,

Organon supports the 340B program and its intended mission of supporting safety net providers in providing patients in need with access to medical care and medications. This letter is intended to provide you notice that Organon is altering its approach to the offering of 340B discounts to contract pharmacies. This change is intended to help reduce diversion and inappropriate claims for discounts and rebates.

Effective July 1, 2023, Organon will only provide products purchased at the 340B price to locations registered as 340B covered entities and will decline to facilitate Bill To/ Ship To orders for all hospital covered entities, subject to the exceptions outlined below. Organon's updated policy will not apply to 340B pricing for 340B contract pharmacy locations for any 340B covered entity that is eligible for the 340B program through their grant status with HRSA or other eligible grants. Federal grantees will continue to remain eligible for Bill To/Ship To arrangements for Organon products at the 340B discounted price and do not need to submit 340B claims.

Any hospital covered entity, regardless of whether it has an in-house pharmacy capable of dispensing 340B purchased drugs to its patients, may designate a single contract pharmacy location if the covered entity provides claims data for the designated single contract pharmacy through 340B ESP™.

Organon is utilizing the 340B ESP™ platform to support this designation. 340B covered entities that haven't already registered an account with 340B ESP™, can make their designation by visiting www.340besp.com/designations. If you have any questions about this initiative, please contact 340B ESP™ at support@340besp.com.

Covered entities must take action by June 16th, 2023 in order for contract pharmacy location designations to take effect on the effective date of this policy.

Organon is committed to ensuring that all 340B covered entities can purchase Organon products at the 340B discounted price. 340B covered entities should work with their contract pharmacy administrators and wholesalers to process any outstanding Bill To/ Ship To orders in advance of the July 1, 2023 effective date. Please refer to the Next Steps and FAQs for more information.

Best Regards,

Andrew Tedeschi
Head of US Market Access and Account Management